Thursday, February 23, 2017

BRIEF-Shire reports positive results in phase 1b study of skin swelling drug Lanadelumab

* No serious adverse events or discontinuations due to

adverse events were observed at all doses studied

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)